# 1 Supplementary Information

# 2 Supplementary Methods

### 3 Cell culture methods

4	Six independent Normal Human Urothelial (NHU) cell lines of finite (non-immortalised)
5	lifespan were used in this study. The cell lines were established as described [1] using
6	anonymous discarded tissue from renal transplant surgery, with UK NHS approval (REC
7	reference 99/095) from the Leeds East Research Ethics Committee. NHU cells were
8	propagated in Keratinocyte Serum-Free Medium containing bovine pituitary extract,
9	recombinant human EGF (KSFM) and additionally supplemented with 30ng/ml cholera toxin.
10	Following expansion, NHU cells were differentiated in the same medium supplemented with
11	5% adult bovine serum and CaCl <sub>2</sub> was added to elevate the [Ca <sup>2+</sup> ] from 0.09 to 2 mM,
12	according to published methods [2]. Differentiated cultures of the six independent cell lines
13	were exposed to IFN $\gamma$ (200U/mL, BioTechne #285-IF) for 7 days and medium was changed
14	every 48 hours. Urothelial mitotic-quiescence and differentiation was largely unaffected by
15	IFNγ-treatment and although there was a significant gain of <i>KRT6A</i> expression, there was no
16	significant loss of transitional epithelial markers and no other indicators of squamous
17	change (Supplementary Table 1).

18

19 mRNA Analysis

Total RNA was collected in TRIzol reagent (Invitrogen) and mRNA-sequencing was
 performed using an Illumina NovaSeq 6000 generating 150bp paired-end reads (Novogene
 UK, Cambridge, UK). All mRNA-sequencing data was deposited at GSE174244. Following

23 standard quality control, gene-level expression values in transcripts per million (TPM) were derived against the Gencode v35 human transcriptome using kallisto v0.46.1 [3]. 24 25 Differentially-expressed genes were identified using the sleuth v0.30.0 [4] implementation 26 of the likelihood ratio test (LRT), accounting for matched genetic backgrounds, generating 27 Benjamini-Hochberg corrected q-values. For volcano plots (performed in R v4.0.4 EnhancedVolcano v1.8.0), fold-change values used a  $log_2(TPM+1)$  transformation to reduce 28 29 the influence of low abundance transcripts. This analysis identified 107 genes that were 30 significantly (q<0.05) >2-fold increased by IFN $\gamma$  and 48 genes whose expression was significantly (q<0.05) more than halved by IFN $\gamma$ -treatment of urothelial tissues 31 32 (Supplementary Table 1).

33

#### 34 Publicly-Available Bladder Cancer Cohort Data

Patient data for four publicly-available bladder cancer cohorts was downloaded following 35 instructions in their relevant publications [5-8]. Two cohorts focussed on non-muscle 36 37 invasive bladder cancer (NMIBC) and from these we extracted only the T1 tumours for 38 further analysis [5, 7]. Two cohorts we of muscle invasive bladder cancer (MIBC) and from 39 these we extracted the tumours transcriptomically classified as the "Basal/Squamous" subtype for further analysis based on the high variability in the IFN<sub>γ</sub>-Signature that we 40 observed in this group [6, 8, 9]. mRNA-sequencing data was remapped to Gencode v35 41 42 human transcriptome using kallisto v0.46.1 where possible [3]. MIBC gene array data from the Lund cohort was utilised as deposited at GSE83586 to generate Combat centered probe 43 44 fluorescence values [8].

#### 46 *IFNγ-signature generation*

All q<0.05 significantly >2-fold IFN $\gamma$ -increased genes were extracted from the TCGA-BLCA [6] 47 48 and UROMOL2021 [7] cohorts of MIBC and NMIBC, respectively. Genes regulated by IFN $\gamma$  in vitro can be regulated predominantly by other mechanisms in tissues and to refine the 49 50 signature, Spearman correlation matrices were calculated to compare all genes with one 51 another. The median Spearman Rho for each gene in comparison with all others was calculated in each cohort. The median Spearman Rho values for the TCGA-BLCA and 52 53 UROMOL2021 cohorts were averaged and only genes with a value greater than 0.5 were 54 retained (n=33; gene list in Supplementary Table 2) to generate a transcriptomic classifier relevant to both NMIBC and MIBC, where all genes were >2-fold increased by IFN $\gamma$  in vitro 55 and closely related to one another in tumours. 56 57 Initial evaluation of the IFN $\gamma$ -signature in tumours was performed on log<sub>2</sub>(TPM+1) data using hierarchical clustering (based on Euclidean distance and complete linkage. This approach 58

59 highlights the relationship between samples in the full cohorts of NMIBC UROMOL2021 [7]

60 (Supplementary Fig. 3) and MIBC TCGA-BLCA [6] (Supplementary Fig. 5).

61

#### 62 *IFNγ-signature analysis*

mRNAseq data expressed as TPMs for tumours from the NMIBC cohorts was combined to
create one large cohort for analysis. For the MIBC cohorts, to allow integration of data
acquired by different methods (TCGA-BLCA mRNA-sequencing [6] with the Lund gene array
[8] data) each cohort was clustered separately into IFNγ-signature high and low groups.
Classification of tumours was performed on log<sub>2</sub>(TPM+1) data using Euclidean distance k

means clustering into two groups of T1 NMIBC tumours (from the UROMOL2021 [7] and
Northwestern Memorial Hospital [5] cohorts) and Basal/Squamous classified [9] MIBC
tumours (TCGA-BLCA [6]). Classification of Basal/Squamous MIBC tumours form the Lund [8]
cohort was performed using Euclidean distance k means clustering into two groups on logtransformed Combat centered probe fluorescence.

73 A single-value IFNγ-signature score was derived by unit-length scaling the log<sub>2</sub>(TPM+1) data 74 (or log-transformed Combat centered probe fluorescence for the Lund cohort [8]) for each 75 gene. Unit-length scaled data for the genes in the signature were then summed on a per 76 patient basis before being re-scaled (again 0-1). This derived a single value IFNγ-signature 77 score that could be ranked to generate Spearman Rho values in comparison with ranked gene expression values (eg *IFNG*) in the various cohorts. The single-value  $IFN\gamma$ -signature 78 79 scores for the combined T1, TCGA-BLCA and Lund cohorts are provided in Supplementary Tables 3, 5 and 6, respectively. 80

81 Survival analysis was performed in Prism v9.3.1 (Graphpad). T1 NMIBC tumours and 82 Basal/Squamous classified MIBC tumours from the different cohorts were pooled to support Kaplan-Meier NMIBC Recurrence Free Survival (RFS) and MIBC Overall Survival (OS) analysis, 83 respectively. Statistical significance of the difference between Kaplan-Meier curves for IFNy-84 signature high and low groups was performed using Mantel-Cox and Gehan-Breslow-85 86 Wilcoxon tests, with hazard ratios calculated using both Mantel-Haenszel and log rank 87 approaches. A Cox proportional hazards regression analysis was performed using the pseudo-88 continuous unit-length scaled IFN<sub>γ</sub>-signature scores to demonstrate that the effects of IFN<sub>γ</sub>-89 signalling persist without dichotomising the tumours.

# 91 TCGA-BLCA mutational signature analysis

TCGA-BLCA legacy mutation data [6] was downloaded from cBioPortal [10]. The single base
substitution (SBS) signature for all tumours was analysed using the "Catalog" input for the
"signal" workflow for mutational signature analysis by comparison against the Catalogue of
Somatic Mutations In Cancer "COSMIC" reference SBS signatures common in bladder tumours
(namely SBS2, SBS4, SBS5 and SBS13; https://signal.mutationalsignatures.com/ [11]).



Supplementary Figure 1 – Urothelial expression of both IFNγ receptor isoform genes was
high but significantly reduced by IFNγ treatment. Mean log<sub>2</sub> fold changes were -0.39 and 0.38 for IFNGR1 and IFNGR2, respectively. Stars following gene names indicate significance
\*\*=p<0.01.</li>



Supplementary Figure 2 – Gain in expression of a broad range of human leukocyte antigen
(HLA) genes. This study used cell derived from six independent donors. Stars following gene
names indicate >2-fold changes with significance \*=q<0.05, \*\*=q<0.01 and \*\*\*=q<0.001.</li>



Supplementary Figure 3 – The full UROMOL2021 NMIBC cohort (n=535; [7]) expression of the 109 110 *IFNγ-signature genes. Tumours were split using hierarchical clustering based on Euclidean* distance with complete linkage. The IFNG gene is not part of the signature but is included 111 112 above to show the lack of sensitivity when relying on IFNG transcript abundance alone. IFNG transcript abundance was significantly correlated with the IFN $\gamma$ -signature (Spearman 113 *Rho=0.57; p=1.02x10<sup>-46</sup>). Tumours are coloured according to the 2021 classification into four* 114 subtypes (Class 1, Class 2a, Class 2b and Class 3) [7]. The heatmap shows enrichment of IFNy 115 responsive gene expression in a subset of the Class 2b group of NMIBC. Lindskrog et al. 116 identified Class 2b as being the most immune-infiltrated tumours [7]. Class 2a tumours were 117 predominantly IFNγ-signature<sup>low</sup> and had the highest recurrence rate in the original 118 publication [7]. 119



121 Supplementary Figure 4 – Heatmap and k means clustering based on expression of the IFNγ-

- signature in the T1 tumours of the Northwestern Memorial Hospital (NMH) cohort (n=99;
- 123 shown with the classifier from the original report [5]). The IFNγ-signature shows a Spearman
- 124 rank correlation of 0.67 ( $p=1.66 \times 10^{-14}$ ) with the IFNG gene in this cohort.



Supplementary Figure 5 – (A) The full TCGA-BLCA MIBC cohort (n=404; [6]) expression of the IFN $\gamma$ -signature genes. Tumours were split using 126 hierarchical clustering based on Euclidean distance with complete linkage. The IFNG gene itself is not part of the signature and has a limited 127 sensitivity for detecting IFNy signalling; however, it does show significant correlation with the IFNy-signature (Spearman Rho=0.83; p=2.86x10<sup>-</sup> 128 129 <sup>102</sup>). Tumours are coloured according to the 2019 consensus classification into six subtypes (Basal/Squamous, Luminal Non-specified, Luminal Papillary, Luminal Unstable, Neuroendocrine-like and Stroma-rich) [9]. The heatmap shows diversity in the IFNy-signature within the 130 Basal/Squamous group of MIBC and so these tumours were evaluated further (Figure 2C). (B) Histological grading of lymphocyte invasion of 131 TCGA-BLCA tumours, showing significant (Chi square=56.63; df=4;  $p=1.48 \times 10^{-11}$ ) differences, including that IFN $\gamma$ -signature low tumours were 132 more likely to contain no lymphocytes. 133





*calculated in this cohort.* 



Supplementary Figure 7 – Basal/Squamous tumours of TCGA-BLCA have paired exomesequencing which allows the analysis of mutations. No significant over-mutation of
individual genes was observed in association with the IFNγ-signature. (A) However, APOBECdriven mutational processes had been significantly more active (as denoted by significant
enrichment of single base substitution signatures "SBS2" and "SBS13") in tumours that
ultimately had higher IFNγ-signature scores. It was not the case that all mutational processes
were more active in forming tumours with a higher IFNγ-signature, as SBS4 and SBS5 were

- 148 not enriched. Significance was analysed by Mann Whitney U test. ns = no significant
- 149 *difference*.
- 150 In silico analysis of the likely effects of mutations on neoantigen load in tumours was
- 151 previously described by TCGA consortium [6]. (B) Analysis of Basal/Squamous tumours of
- 152 TCGA-BLCA cohort showed a significantly higher predicted neoantigen load in the context of
- 153 higher IFNγ-signalling (p=0.0139). (C) Furthermore, linear regression analysis confirmed a
- 154 significant relationship between predicted neoantigen load and IFNγ-signature score
- 155 *(p=0.0012)*.
- 156

# 157 Supplementary References

- 158 [1] Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro:
- 159 proliferation and induction of stratification. Lab Invest. 1994;71:583-94.
- 160 [2] Cross WR, Eardley I, Leese HJ, Southgate J. A biomimetic tissue from cultured normal human
- urothelial cells: analysis of physiological function. Am J Physiol Renal Physiol. 2005;289:F459-68.
- 162 [3] Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat163 Biotechnol. 2016;34:525-7.
- 164 [4] Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq
- 165 incorporating quantification uncertainty. Nat Methods. 2017;14:687-90.
- 166 [5] Robertson AG, Groeneveld CS, Jordan B, et al. Identification of Differential Tumor Subtypes of T1
- 167 Bladder Cancer. Eur Urol. 2020;78:533-7.
- 168 [6] Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-
- 169 Invasive Bladder Cancer. Cell. 2017;171:540-56 e25.
- 170 [7] Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic
- 171 molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.
- 172 [8] Sjodahl G, Eriksson P, Liedberg F, Hoglund M. Molecular classification of urothelial carcinoma:
- 173 global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242:113-25.
- 174 [9] Kamoun A, Reynies A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive
- 175 Bladder Cancer. Eur Urol. 2019.
- 176 [10] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for
- 177 exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-4.
- 178 [11] Degasperi A, Amarante TD, Czarnecki J, et al. A practical framework and online tool for
- 179 mutational signature analyses show intertissue variation and driver dependencies. Nature Cancer.
- 180 2020;1:249-63.